Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors.
about
Markers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where Are We Now and What Should Be Next?Optimal combination of antiangiogenic therapy for hepatocellular carcinomaPET and MR imaging: the odd couple or a match made in heaven?Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancerQuantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imagingImaging biomarker roadmap for cancer studiesMixed-effects modeling of clinical DCE-MRI data: application to colorectal liver metastases treated with bevacizumab.Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors.A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.Identification of target genes of cediranib in alveolar soft part sarcoma using a gene microarray.Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies.In-vivo visualization of tumor microvessel density and response to anti-angiogenic treatment by high resolution MRI in miceVascular endothelial growth factor receptor-2 in breast cancer.Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study.Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysisPhase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastomaPhase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).Assessment of acute antivascular effects of vandetanib with high-resolution dynamic contrast-enhanced computed tomographic imaging in a human colon tumor xenograft model in the nude ratThe combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer.Anti-VEGF Cancer Therapy in Nephrology PracticeImaging in clinical trials.Effect of cediranib, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, in a mouse model of choroidal neovascularization.Response of HT29 colorectal xenograft model to cediranib assessed with 18 F-fluoromisonidazole positron emission tomography, dynamic contrast-enhanced and diffusion-weighted MRI.Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranibA phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors.Cediranib for metastatic alveolar soft part sarcomaBiomarkers of response and resistance to antiangiogenic therapy.Liver cancer: Targeted future optionsThe effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors.Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer.PPemd26, an anthraquinone derivative, suppresses angiogenesis via inhibiting VEGFR2 signalling.Novel therapeutic strategies for targeting liver cancer stem cells.Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: a phase II North Central Cancer Treatment Group Clinical Trial.Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer.Biomarkers in tumor angiogenesis and anti-angiogenic therapy.Clinical development of VEGF signaling pathway inhibitors in childhood solid tumors.Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program.Functional imaging: what evidence is there for its utility in clinical trials of targeted therapies?
P2860
Q26752752-BBBAE944-5E60-43DE-BE78-EB01CD422CC1Q26799458-8D150463-D727-4479-801C-743157526882Q26851721-EEB9AE43-249B-4BC6-A4BB-C054895843B1Q27024235-2802AADF-F3B7-4729-A5DC-A5BE46DAE73DQ27346895-4360D6CA-EF40-416F-9588-74A4E6F7C7C6Q30242020-94066831-E2DE-4913-82DC-75808C855A39Q30806067-72421C29-5F03-49CD-9D54-3DDBFA88263CQ33414769-BB1457EB-68EE-4016-8E9B-5E609EFE2584Q33415009-6D38A93D-7E1A-4E8D-B362-E21F84C67588Q33598883-49FCF817-48C4-4654-8BA0-9FBA46AFD726Q33710574-940BB448-B579-4D1B-9A05-5A58ACC25A4AQ33874179-4AC60C95-F0C0-477C-BE70-3C6482B40D7FQ33900712-EC1A4815-DA79-4357-8025-59F216AC28ACQ33912620-623666B6-840B-497A-A71D-F751C3839178Q33918044-1820388D-196D-442F-A90E-D385800D5D98Q33926377-449A4FF4-2312-4AC5-AA91-C5B50CFCD482Q33990834-D598ACFE-5E36-4204-84CD-11A3C95AB5A5Q34026037-C0990170-1C00-48A1-A65E-EDED75DD7100Q34105344-2C4875B8-57D3-4D2B-85BC-82AECA009A5FQ34134697-F0C68C83-63D4-4238-BFBC-75D8FDE1A29BQ34152125-E9BBE352-10E7-4B50-90CD-10AAC3479B3AQ34256382-74017F89-4FCF-4A93-A1D0-BD08CDAAE21AQ34272439-DFB34A94-7EDB-49BB-BB0A-40B8AB2AD775Q34331739-833DEDC6-3DE5-4036-8D18-E1FCEE8F734BQ34354522-EF7E38DC-6E0E-47DD-9259-3FCD7B81A244Q34488671-973E68F7-C9A3-42B7-93AE-E68D6C2E858EQ34651131-A3990AC7-59B2-4224-8B34-CE1455B289FEQ34673567-23A3EB4D-F352-4593-A540-B953E934B44BQ34695180-E89040DD-E0B6-468A-999B-47001E4CBC64Q34725749-21AE9CD0-6A6E-450E-9BE6-B5D58337C7C6Q34854658-C1744A41-B885-4E39-B716-D307A820D5D6Q34914220-E2800883-E172-4020-A472-B92F520B08EEQ34940971-6B19DC04-CD24-4D71-9F5C-84BFF1A82469Q35057364-35C0F394-4E0B-4173-B988-B28588D2A53EQ35078518-84041784-FDF2-412D-B648-B55963C4A866Q35419004-D19AD6F1-368D-4D8E-8055-E4848BC956BCQ35536088-EE21A4FE-FE2A-4673-ADE9-17F666F3EE05Q35599819-BA478A71-AC43-4FE0-B0FB-76342BB521FBQ35659433-450EB6D1-A4C3-4317-8488-6F6CEBEA8B80Q35879814-35BBA452-103B-4BB2-8313-B220F559A800
P2860
Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Phase I clinical study of AZD2 ...... ts with advanced solid tumors.
@en
Phase I clinical study of AZD2 ...... ts with advanced solid tumors.
@nl
type
label
Phase I clinical study of AZD2 ...... ts with advanced solid tumors.
@en
Phase I clinical study of AZD2 ...... ts with advanced solid tumors.
@nl
prefLabel
Phase I clinical study of AZD2 ...... ts with advanced solid tumors.
@en
Phase I clinical study of AZD2 ...... ts with advanced solid tumors.
@nl
P2093
P356
P1476
Phase I clinical study of AZD2 ...... ts with advanced solid tumors.
@en
P2093
Clemens Unger
Helen Young
Hubert Blum
Jan Harder
Jane Robertson
Joachim Drevs
Juliane M Jürgensmeier
Klaus Mross
Michael Medinger
Owain Saunders
P304
P356
10.1200/JCO.2006.07.2066
P407
P577
2007-07-01T00:00:00Z